logo
Number of Shares and Voting Rights of Innate Pharma as of April 25, 2025

Number of Shares and Voting Rights of Innate Pharma as of April 25, 2025

Business Wire28-04-2025

MARSEILLE, France--(BUSINESS WIRE)--Regulatory News:
Pursuant to the article L. 233-8 II of the French 'Code de Commerce' and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or ' AMF ') General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (' Innate ' or the ' Company ') releases its total number of shares outstanding as well as its voting rights as at April 25, 2025:
(1) The total number of theoretical voting rights (or 'gross' voting rights) is used as the basis for calculating the crossing of shareholding thresholds. In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to which voting rights are attached, including shares whose voting rights have been suspended. The total number of theoretical voting rights includes voting rights attached to AGAP 2016, i.e. 130 voting rights for the AGAP 2016-1 and 111 voting rights for the AGAP 2016-2. No voting rights attached to AGAP 2017.
(2) The total number of exercisable voting rights (or 'net' voting rights) is calculated without taking into account the shares held in treasury by the Company, with suspended voting rights. It is released so as to ensure that the market is adequately informed, in accordance with the recommendation made by the AMF on July 17, 2007.
About Innate Pharma
Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through three therapeutic approaches: multi-specific NK Cell Engagers via its ANKET ® (A ntibody-based NK cell E ngager T herapeutics) proprietary platform, Antibody Drug Conjugates (ADC) and monoclonal antibodies (mAbs).
Innate's portfolio includes several ANKET ® drug candidates to address multiple tumor types as well as IPH4502, a differentiated ADC in development in solid tumors. In addition, anti-KIR3DL2 mAb lacutamab is developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, and anti-NKG2A mAb monalizumab is developed with AstraZeneca in non-small cell lung cancer.
Innate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients.
Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.
Learn more about Innate Pharma at www.innate-pharma.com and follow us on LinkedIn and X.
Information about Innate Pharma shares
Disclaimer on forward-looking information and risk factors
This press release contains certain forward-looking statements, including those within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. The use of certain words, including 'anticipate,' 'believe,' 'can,' 'could,' 'estimate,' 'expect,' 'may,' 'might,' 'potential,' 'expect' 'should,' 'will,' or the negative of these and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company's reliance on third parties to manufacture its product candidates, the Company's commercialization efforts and the Company's continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties, which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ('Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority ('AMF'), which is available on the AMF website http://www.amf-france.org or on Innate Pharma's website, and public filings and reports filed with the U.S. Securities and Exchange Commission ('SEC'), including the Company's Annual Report on Form 20-F for the year ended December 31, 2023, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company's website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release.
In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by the Company or any other person that the Company will achieve its objectives and plans in any specified time frame or at all. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

eXp Realty Dominates 2025 RealTrends Rankings With 757 Agents and Teams Honored
eXp Realty Dominates 2025 RealTrends Rankings With 757 Agents and Teams Honored

Yahoo

time21 minutes ago

  • Yahoo

eXp Realty Dominates 2025 RealTrends Rankings With 757 Agents and Teams Honored

40 eXp Realty agents and teams break into the elite 'The Thousand' list, and the firm claims #1 spot for transactions nationwideBELLINGHAM, Wash., June 10, 2025 (GLOBE NEWSWIRE) -- eXp Realty®, 'the most agent-centric real estate brokerage on the planet™' and the core subsidiary of eXp World Holdings, Inc. (Nasdaq: EXPI), today announced that a record-breaking 757 of its agents and teams have been named among the top real estate professionals in the country, according to the 2025 RealTrends Verified America's Best List. With fewer than 0.1% of agents qualifying nationwide, inclusion in the RealTrends rankings is a rare achievement that reflects exceptional production and service. Adding to the celebration, eXp Realty also ranked as the: #1 Brokerage in the U.S. by Transaction Sides #3 Brokerage in the U.S. by Sales Volume These accolades underscore eXp's continued dominance in the real estate space and its commitment to supporting agents through a robust cloud-based platform, best-in-class tools, and unparalleled collaboration opportunities. 'At eXp Realty, our agents are our greatest asset. Seeing 757 of our professionals earn recognition on the RealTrends lists is both humbling and energizing,' said Leo Pareja, CEO of eXp Realty. 'This success is a direct result of our commitment to providing agents with the tools, model, and culture they need to thrive. We are building something extraordinary, and this achievement is a powerful testament to the strength of our community.' With a mission to empower agents to build better businesses, eXp Realty continues to redefine what's possible in real estate, offering top-tier financial incentives, cutting-edge technology, and a globally connected network – all of which contribute to driving results for clients and professionals alike. About eXp World Holdings, Inc. eXp World Holdings, Inc. (Nasdaq: EXPI) (the 'Company') is the holding company for eXp Realty® and SUCCESS® Enterprises. eXp Realty is the largest independent real estate brokerage in the world, with over 81,000 agents across 27 countries. As a cloud-based, agent-centric brokerage, eXp Realty provides real estate agents industry-leading commission splits, revenue share, equity ownership opportunities, and a global network that empowers agents to build thriving businesses. For more information about eXp World Holdings, Inc., visit: SUCCESS® Enterprises, anchored by SUCCESS® magazine, has been a trusted name in personal and professional development since 1897. As part of the eXp ecosystem, it offers agents access to valuable resources to enhance their skills, grow their businesses, and achieve long-term success. For more information about SUCCESS, visit Safe Harbor and Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements reflect the Company's and its management's current expectations but involve known and unknown risks and uncertainties that could impact actual results materially. These statements include, but are not limited to, statements regarding the anticipated success of agents or teams joining eXp Realty, future production goals or volume projections, and participation in or benefits derived from the Company's platform, tools, compensation model, or equity programs. Important factors that may cause actual results to differ materially and adversely from those expressed in forward-looking statements include real estate market fluctuations, changes in agent retention or recruitment, the Company's ability to expand successfully in international markets, competitive pressures, regulatory changes, and other risks detailed from time to time in the Company's Securities and Exchange Commission filings, including but not limited to the most recently filed Quarterly Reports on Form 10-Q and Annual Report on Form 10-K. We do not undertake any obligation to update these statements except as required by law. Media Relations Contact:eXp World Holdings, Investor Relations Contact:Denise Garciainvestors@ A photo accompanying this announcement is available at

GenAI Growth, Creative Cloud Pricing in Focus as Adobe Reports Q2
GenAI Growth, Creative Cloud Pricing in Focus as Adobe Reports Q2

Yahoo

time25 minutes ago

  • Yahoo

GenAI Growth, Creative Cloud Pricing in Focus as Adobe Reports Q2

Adobe (NASDAQ:ADBE) is set to release its fiscal Q2 results on Thursday after markets close, and analysts say the spotlight will be squarely on the company's generative AI roadmap and competitive strategy. Morgan Stanley believes investor worries over Adobe's positioning in the AI space have contributed to the stock underperforming large-cap software peers by roughly 15 percentage points over the past three months. In a note Tuesday, analyst Keith Weiss said low expectations paired with potential gains in annual recurring revenue for Adobe's Digital Media business create a favorable risk-reward setup. The firm rates the stock Overweight with a $510 price target. Weiss also pointed to Adobe's push for innovation at the high end of its product line and more flexible pricing for smaller customers as key to boosting growth. Jefferies echoed that optimism, highlighting Adobe's 7% price hike for Creative Cloud renewals starting June 17. Analyst Brent Thill said the move should help offset headwinds from prior pricing changes and potentially lift 2026 results. Jefferies maintains a Buy rating and a $590 price target. Consensus estimates call for adjusted earnings of $4.97 per share on revenue of $5.8 billion. That compares with $5.08 in adjusted EPS and $5.71 billion in revenue from the previous quarter. Jefferies also flagged currency movements as a potential boost to revenue, estimating a 1 percentage point tailwind compared with current expectations of a neutral to slight headwind. This article first appeared on GuruFocus.

Be Sure To Check Out Nasdaq, Inc. (NASDAQ:NDAQ) Before It Goes Ex-Dividend
Be Sure To Check Out Nasdaq, Inc. (NASDAQ:NDAQ) Before It Goes Ex-Dividend

Yahoo

time26 minutes ago

  • Yahoo

Be Sure To Check Out Nasdaq, Inc. (NASDAQ:NDAQ) Before It Goes Ex-Dividend

Readers hoping to buy Nasdaq, Inc. (NASDAQ:NDAQ) for its dividend will need to make their move shortly, as the stock is about to trade ex-dividend. The ex-dividend date is one business day before a company's record date, which is the date on which the company determines which shareholders are entitled to receive a dividend. The ex-dividend date is of consequence because whenever a stock is bought or sold, the trade takes at least one business day to settle. This means that investors who purchase Nasdaq's shares on or after the 13th of June will not receive the dividend, which will be paid on the 27th of June. The company's next dividend payment will be US$0.27 per share, and in the last 12 months, the company paid a total of US$1.08 per share. Based on the last year's worth of payments, Nasdaq has a trailing yield of 1.3% on the current stock price of US$85.65. Dividends are an important source of income to many shareholders, but the health of the business is crucial to maintaining those dividends. So we need to investigate whether Nasdaq can afford its dividend, and if the dividend could grow. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. Dividends are typically paid out of company income, so if a company pays out more than it earned, its dividend is usually at a higher risk of being cut. That's why it's good to see Nasdaq paying out a modest 43% of its earnings. Generally speaking, the lower a company's payout ratios, the more resilient its dividend usually is. Check out our latest analysis for Nasdaq Click here to see the company's payout ratio, plus analyst estimates of its future dividends. Companies with consistently growing earnings per share generally make the best dividend stocks, as they usually find it easier to grow dividends per share. If earnings fall far enough, the company could be forced to cut its dividend. With that in mind, we're encouraged by the steady growth at Nasdaq, with earnings per share up 7.3% on average over the last five years. Many investors will assess a company's dividend performance by evaluating how much the dividend payments have changed over time. In the last 10 years, Nasdaq has lifted its dividend by approximately 18% a year on average. We're glad to see dividends rising alongside earnings over a number of years, which may be a sign the company intends to share the growth with shareholders. Should investors buy Nasdaq for the upcoming dividend? It has been growing its earnings per share somewhat in recent years, although it reinvests more than half its earnings in the business, which could suggest there are some growth projects that have not yet reached fruition. We think this is a pretty attractive combination, and would be interested in investigating Nasdaq more closely. While it's tempting to invest in Nasdaq for the dividends alone, you should always be mindful of the risks involved. Case in point: We've spotted 1 warning sign for Nasdaq you should be aware of. If you're in the market for strong dividend payers, we recommend checking our selection of top dividend stocks. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store